OpenAI is an AI research and deployment company, best known for ChatGPT and its GPT models. In life sciences, it offers a specialized model and a set of research tools aimed at drug discovery, genomics, and translational medicine.

GPT-Rosalind (launched April 2026) is a frontier reasoning model for drug discovery, genomics analysis, protein reasoning, and scientific research workflows. It is available in ChatGPT, Codex, and the API for qualified customers through a trusted-access program. It is built to support evidence synthesis, hypothesis generation, experimental planning, and other multi-step research tasks. A June 2026 update paired it with GPT-5.5's agentic coding and tool use, with stronger performance in medicinal chemistry, genomics, and wet lab troubleshooting. In September 2026, OpenAI moved it out of research preview to eligible organizations globally, with published pricing starting October 5, 2026.

Life Sciences plugins for Codex are available to all users. The Life Sciences Research plugin and the Life Sciences NGS Analysis plugin add sourced evidence retrieval, biological interpretation, and bioinformatics execution to one workspace. The research plugin gives access to more than 50 public multi-omics databases, literature sources, and biology tools. Qualified enterprise users can power both plugins with GPT-Rosalind. Codex also includes interactive viewers for sequence, alignment, and structure files, so scientists can inspect the underlying data while the model works.

Access is limited to organizations doing legitimate research with clear public benefit, with governance and security controls in place. OpenAI also offers a managed workspace for qualified organizations without an Enterprise account.

Life sciences customers and ecosystem partners include Amgen, Novo Nordisk, Moderna, Thermo Fisher Scientific, the Allen Institute, Oracle Health and Life Sciences, NVIDIA, Benchling, and UCSF School of Pharmacy. McKinsey, BCG, and Bain advise organizations on adoption. OpenAI also works with Los Alamos National Laboratory on AI-guided protein and catalyst design.